# FCRL2

## Overview
FCRL2, or Fc receptor-like 2, is a gene that encodes a transmembrane protein involved in the regulation of immune responses, particularly within B cells. The protein, also named Fc receptor-like 2, is predominantly expressed in memory B cells and plays a crucial role in modulating B cell receptor (BCR)-mediated signaling. Unlike classical Fc receptors, FCRL2 does not bind immunoglobulins, highlighting its unique function in immune regulation (Jackson2010FcRLike). The protein contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that, upon phosphorylation, recruit the SHP-1 phosphatase, leading to the inhibition of signaling pathways essential for B cell activation (Jackson2010FcRLike; Shabani2014Ligation). FCRL2's expression and function are significant in various clinical contexts, including chronic lymphocytic leukemia and IgA nephropathy, where its expression levels serve as potential prognostic markers (Li2008FCRL2; Zhong2021Expression).

## Function
The FCRL2 gene encodes a transmembrane protein that plays a significant role in the regulation of B cell receptor (BCR)-mediated signaling in B cells. It is predominantly expressed in memory B cells and is involved in modulating immune responses by inhibiting BCR signaling pathways. FCRL2 contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, which, upon phosphorylation, recruit the SHP-1 phosphatase. This recruitment leads to the attenuation of calcium mobilization and the dephosphorylation of proteins such as p38 and ERK MAPKs, crucial for B cell activation (Jackson2010FcRLike; Shabani2014Ligation).

FCRL2 is primarily active in peripheral lymphoid tissues, such as the spleen and lymph nodes, and is most abundant in memory B cells. It is not found on precursor B cells or plasma cells in the bone marrow (Davis2007Fc). The protein's inhibitory function is thought to help maintain memory B cell quiescence and regulate immune responses, potentially preventing autoimmunity (Jackson2010FcRLike; Shabani2014Ligation). Despite its homology with classical Fc receptors, FCRL2 does not bind immunoglobulins, indicating a unique role in immune regulation (Jackson2010FcRLike).

## Clinical Significance
FCRL2 expression has significant clinical implications, particularly in chronic lymphocytic leukemia (CLL). Elevated FCRL2 expression is strongly associated with the mutated IGHV (MT-CLL) subtype, which is linked to a more indolent disease course and favorable prognosis. This makes FCRL2 a valuable prognostic marker, potentially more effective than traditional markers like CD38 and ZAP-70 in predicting IGHV mutation status and clinical progression in CLL (Li2008FCRL2). High FCRL2 expression correlates with a longer median time to first therapy, indicating its role in disease management (Li2008FCRL2).

In IgA nephropathy (IgAN), FCRL2 expression is significantly down-regulated compared to healthy controls. This alteration in expression may be associated with the disease, although a direct causal relationship has not been established (Zhong2021Expression). 

FCRL2 has also been implicated in skin cutaneous melanoma, where lower expression levels are associated with poor overall survival, suggesting its potential role in cancer prognosis (Liu2020Development). Additionally, a variant in the FCRL2 gene has been linked to electrocardiogram parameters, although its exact contribution to cardiac function remains unclear (Silva2016A).

## Interactions
FCRL2 interacts with the SH2-domain containing phosphatase SHP-1 following coligation with the B cell receptor (BCR). This interaction is dependent on the phosphorylation of tyrosine residues within the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) of FCRL2, specifically at tyrosines 474 and 502. The phosphorylation of these residues recruits SHP-1, which plays a crucial role in inhibiting BCR-mediated signaling pathways, including calcium mobilization and the phosphorylation of proteins in the MAPK pathway, such as p38 and ERK1/2 (Jackson2008The).

FCRL2 does not recruit SHP-2 or SHIP, indicating a specific interaction with SHP-1. This specificity is further supported by experiments showing that SHP-1 co-immunoprecipitates with chimeric proteins containing the wild-type cytoplasmic region of FCRL2, but not with ITIM mutants (Jackson2008The). The interaction with SHP-1 suggests that FCRL2 has an inhibitory role in B cell signaling, particularly in memory B cells, where it is preferentially expressed (Jackson2008The).


## References


[1. (Davis2007Fc) Randall S. Davis. Fc receptor-like molecules. Annual Review of Immunology, 25(1):525–560, April 2007. URL: http://dx.doi.org/10.1146/annurev.immunol.25.022106.141541, doi:10.1146/annurev.immunol.25.022106.141541. This article has 164 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1146/annurev.immunol.25.022106.141541)

[2. (Shabani2014Ligation) Mahdi Shabani, Ali Ahmad Bayat, Mahmood Jeddi‐Tehrani, Hodjatallah Rabbani, Mohammad Hojjat‐Farsangi, Cristina Ulivieri, Zahra Amirghofran, Cosima Tatiana Baldari, and Fazel Shokri. Ligation of human fc receptor like‐2 by monoclonal antibodies down‐regulates b‐cell receptor‐mediated signalling. Immunology, 143(3):341–353, October 2014. URL: http://dx.doi.org/10.1111/imm.12311, doi:10.1111/imm.12311. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/imm.12311)

[3. (Silva2016A) Claudia T. Silva, Irina V. Zorkoltseva, Najaf Amin, Ayşe Demirkan, Elisabeth M. van Leeuwen, Jan A. Kors, Marten van den Berg, Bruno H. Stricker, André G. Uitterlinden, Anatoly V. Kirichenko, Jacqueline C. M. Witteman, Rob Willemsen, Ben A. Oostra, Tatiana I. Axenovich, Cornelia M. van Duijn, and Aaron Isaacs. A combined linkage and exome sequencing analysis for electrocardiogram parameters in the erasmus rucphen family study. Frontiers in Genetics, November 2016. URL: http://dx.doi.org/10.3389/fgene.2016.00190, doi:10.3389/fgene.2016.00190. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2016.00190)

[4. (Jackson2008The) Tanisha Anne Jackson, Christopher L. Haga, Goetz R. A. Ehrhardt, Randall S. Davis, and Max D. Cooper. The role of fc receptor‐like 2 in b cell signaling. The FASEB Journal, March 2008. URL: http://dx.doi.org/10.1096/fasebj.22.1_supplement.842.1, doi:10.1096/fasebj.22.1_supplement.842.1. This article has 0 citations.](https://doi.org/10.1096/fasebj.22.1_supplement.842.1)

[5. (Jackson2010FcRLike) Tanisha A. Jackson, Christopher L. Haga, Götz R. A. Ehrhardt, Randall S. Davis, and Max D. Cooper. Fcr-like 2 inhibition of b cell receptor-mediated activation of b cells. The Journal of Immunology, 185(12):7405–7412, December 2010. URL: http://dx.doi.org/10.4049/jimmunol.1002305, doi:10.4049/jimmunol.1002305. This article has 41 citations.](https://doi.org/10.4049/jimmunol.1002305)

[6. (Liu2020Development) Yu Liu, Yiding Chen, Xianyu Hu, Jialin Meng, and Xiaojing Li. Development and validation of the b cell-associated fc receptor-like molecule-based prognostic signature in skin cutaneous melanoma. BioMed Research International, 2020:1–11, August 2020. URL: http://dx.doi.org/10.1155/2020/8509805, doi:10.1155/2020/8509805. This article has 3 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2020/8509805)

[7. (Li2008FCRL2) Fu Jun Li, Shouluan Ding, Jicun Pan, Mikhail A. Shakhmatov, Elena Kashentseva, Jiongru Wu, Yufeng Li, Seng-jaw Soong, Nicholas Chiorazzi, and Randall S. Davis. Fcrl2 expression predicts ighv mutation status and clinical progression in chronic lymphocytic leukemia. Blood, 112(1):179–187, July 2008. URL: http://dx.doi.org/10.1182/blood-2008-01-131359, doi:10.1182/blood-2008-01-131359. This article has 42 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2008-01-131359)

[8. (Zhong2021Expression) Zhong Zhong, Dianchun Shi, Mengjiao Xiao, Dongying Fu, Shaozhen Feng, Qingyu Kong, Jianbo Li, and Zhijian Li. Expression profile of fc receptor-like molecules in patients with iga nephropathy. Human Immunology, 82(3):186–192, March 2021. URL: http://dx.doi.org/10.1016/j.humimm.2021.01.011, doi:10.1016/j.humimm.2021.01.011. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.humimm.2021.01.011)